These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24906898)

  • 1. Antiphospholipid syndrome: a recurrent cardiac thromboembolic insult in spite of optimal anticoagulation.
    Monteiro AV; Branco LM; de Sousa L; Ferreira RC
    Reumatol Clin; 2015; 11(3):177-8. PubMed ID: 24906898
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent thromboembolism, adenocarcinoma and antiphospholipid syndrome.
    Kim JS; Choi EJ
    Cerebrovasc Dis; 2002; 14(3-4):266-7. PubMed ID: 12403965
    [No Abstract]   [Full Text] [Related]  

  • 3. Emboli shower: Beware of the catastrophe!!
    J Paediatr Child Health; 2018 Jan; 54(1):100. PubMed ID: 29314391
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment failure of direct oral anticoagulants in anti-phospholipid syndrome.
    Johnsen S; Lauvsnes MB; Omdal R
    Scand J Rheumatol; 2018 Sep; 47(5):427-428. PubMed ID: 29297243
    [No Abstract]   [Full Text] [Related]  

  • 5. Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation.
    Miesbach W; Scharrer I; Asherson RA
    Clin Rheumatol; 2004 Jun; 23(3):256-61. PubMed ID: 15168158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
    Cohen H; Machin SJ
    Lupus; 2010 Apr; 19(4):486-91. PubMed ID: 20353992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome.
    Bakshi J; Stevens R
    Lupus; 2013 Jul; 22(8):865-7. PubMed ID: 23740031
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenal hemorrhage causing adrenal insufficiency in a patient with antiphospholipid syndrome: increased adrenal 18F-FDG uptake.
    Boneschansker L; Nijland M; Glaudemans AW; van der Meulen SB; Kluin PM; Dullaart RP
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3014-5. PubMed ID: 22701015
    [No Abstract]   [Full Text] [Related]  

  • 10. Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome.
    O'Neill D; Magaldi J; Dobkins D; Greco T
    Arch Intern Med; 1995 Feb; 155(3):325-7. PubMed ID: 7832605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome.
    Wittkowsky AK; Kino KJ
    Pharmacotherapy; 1995; 15(4):517-21. PubMed ID: 7479207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation for thromboembolism and anticardiolipin-antibody positivity in Lemierre disease.
    Kaushik P; Lampman JH; Kaushik R
    Am J Med; 2008 Apr; 121(4):e11; author reply e13. PubMed ID: 18374669
    [No Abstract]   [Full Text] [Related]  

  • 13. Recurrent refractory arterial thromboembolism in a patient with anti-phospholipid antibody syndrome.
    Sakakibara K; Matsumoto M; Motohashi S; Suzuki S
    Intern Med; 2013; 52(10):1145-6. PubMed ID: 23676608
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antiphospholipid syndrome: from diagnosis to treatment].
    Martinović D; Radić M; Fabijanić D; Fabijanić A
    Lijec Vjesn; 2007; 129(8-9):281-5. PubMed ID: 18198628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential failure of the International Normalized Ratio (INR) System in the monitoring of oral anticoagulation in patients with lupus anticoagulants.
    Della Valle P; Crippa L; Safa O; Tomassini L; Pattarini E; Vigano-D'Angelo S; Grazia Sabbadini M; D'Angelo A
    Ann Med Interne (Paris); 1996 Sep; 147 Suppl 1():10-4. PubMed ID: 8952752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
    Finazzi G; Marchioli R; Brancaccio V; Schinco P; Wisloff F; Musial J; Baudo F; Berrettini M; Testa S; D'Angelo A; Tognoni G; Barbui T
    J Thromb Haemost; 2005 May; 3(5):848-53. PubMed ID: 15869575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiphospholipid syndrome: patterns of life-threatening and severe recurrent vascular complications.
    Insko EK; Haskal ZJ
    Radiology; 1997 Feb; 202(2):319-26. PubMed ID: 9015050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome.
    Özgür G; Beyan C
    Transfus Apher Sci; 2018 Feb; 57(1):13-15. PubMed ID: 29478799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiphospholipid syndrome with anti-prothrombin autoantibodies in a patient with an axial-flow left ventricular assist device.
    Wadia Y; Thiagarajan P; Delgado R; Allison P; Robertson K; Frazier OH
    J Heart Lung Transplant; 2005 Aug; 24(8):1133-6. PubMed ID: 16102458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The treatment of venous thromboembolism in special populations.
    Rondina MT; Pendleton RC; Wheeler M; Rodgers GM
    Thromb Res; 2007; 119(4):391-402. PubMed ID: 16879860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.